Data / New clinical trials / Estonia
New clinical trials in Estonia: 60 since Nov 2024
The full list. New clinical trials with a site in Estonia: 60 rows for $5, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 2 rows a month. The new rows come each week by email, $19 a month.
Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery.
For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/country/estonia, and every list with its row count and price is at https://specstream.ai/data/lists.json.
Updated October 1, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).
60 clinical studies with a site in Estonia were first posted on ClinicalTrials.gov from November 12, 2024 to October 1, 2026; 32 have an industry sponsor and 43 are recruiting or about to. The newest, NCT07851025, was posted on October 1, 2026: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency... (AstraZeneca).
The request: Every new clinical trial with a site in Estonia, with the sponsor, phase, conditions and the listed contact. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.
- 60New trials
- 32Industry sponsored
- 43Recruiting or not yet
- October 1, 2026Latest posted
Newest trials
The newest 60 of 60, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.
| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
|---|---|---|---|---|---|---|---|---|---|
| October 1, 2026 | NCT07851025 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced... | AstraZeneca | Phase 3 | Recruiting | Epithelial Ovarian Cancer | 950 | Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Colombia... | clinicaltrials.gov |
| September 29, 2026 | NCT07846111 | Safety and Feasibility of the INGA Sensor System for Fetal and Uterine Monitoring During Cervical Ripening | Aalto University | Not applicable | Not yet recruiting | Induced Labor, Cervical Ripening, Cervical Ripening and Induction of Labor, Balloon Catheter for Labor Induction | 15 | Estonia | clinicaltrials.gov |
| September 24, 2026 | NCT07839845 | AIDAVA G1 LDL-C Substudy Protocol | North Estonia Medical Centre | Observational | Completed | Myocardial Infarction | 37 | Estonia | clinicaltrials.gov |
| September 18, 2026 | NCT07828769 | The Effect of Orofacial Myofunctional Therapy on Neuromuscular Outcomes and Orofacial Function in Children and Adolescents in Estonia | Tartu University Hospital | Not applicable | Not yet recruiting | Orofacial Myofunctional Disorders | 80 | Estonia | clinicaltrials.gov |
| August 11, 2026 | NCT07757412 | Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple... | Odense University Hospital | Phase 2 | Not yet recruiting | Multiple Myeloma Progression | 50 | Denmark, Estonia, Finland, Norway | clinicaltrials.gov |
| May 28, 2026 | NCT07610356 | Predictors of Transmural Non-Occlusive Mesenteric Ischemia in ICU Patients With Suspected Acute Mesenteric Ischemia | University of Tartu | Observational | Recruiting | Non-Occlusive Mesenteric Ischaemia (NOMI), Acute Mesenteric Ischemia | 150 | Estonia | clinicaltrials.gov |
| May 13, 2026 | NCT07582562 | Risk Factors for Hypoparathyroidism Following Thyroidectomy | Tartu University Hospital | Observational | Recruiting | Post-Surgical Hypoparathyroidism | 300 | Estonia | clinicaltrials.gov |
| May 12, 2026 | NCT07579390 | Effects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE) | Helsinki University Central Hospital | Not applicable | Active not recruiting | Acute Kidney Failure, Renal Replacement Therapy for Acute Kidney Injury in ICU, Sedation in Intensive Care Unit... | 3,500 | Australia, Belgium, Estonia, Finland, Germany, Italy, Luxembourg, New Zealand... | clinicaltrials.gov |
| May 11, 2026 | NCT07577570 | Calcium Replacement Therapy in Postoperative Hypoparathyroidism | Tartu University Hospital | Not applicable | Recruiting | Post-Thyroidectomy Hypoparathyroidism Treatment | 50 | Estonia | clinicaltrials.gov |
| April 29, 2026 | NCT07556900 | Exploring the Potential of Artificial Intelligence for Earlier Breast Cancer Detection: A Retrospective Multi-Reader Study Based on... | Mammograaf Radioloogiakliinik | Observational | Active not recruiting | Breast Cancer, AI (Artificial Intelligence), Early Detection of Cancer | 785 | Estonia | clinicaltrials.gov |
| April 22, 2026 | NCT07546500 | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian... | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 3 | Recruiting | Ovarian Cancer | 420 | Argentina, Australia, Belgium, Brazil, Canada, Croatia, Denmark, Estonia... | clinicaltrials.gov |
| March 27, 2026 | NCT07497087 | A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis | Boehringer Ingelheim | Phase 3 | Recruiting | Systemic Sclerosis | 448 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | clinicaltrials.gov |
| March 24, 2026 | NCT07491549 | The Effect of Pain Education Group Therapy and Its Impact on Chronic Pain, Kinesiophobia, and Physical Activity | University of Tartu | Not applicable | Recruiting | Chronic Pain | 50 | Estonia | clinicaltrials.gov |
| March 24, 2026 | NCT07490730 | Antegrade Transcystic Balloon Dilatation of the Papillary Sphincter During Emergency Laparoscopic Cholecystectomy for Common Bile Duct... | North Estonia Medical Centre | Observational | Completed | Cholelithiasis | 100 | Estonia | clinicaltrials.gov |
| March 16, 2026 | NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and... | Boehringer Ingelheim | Phase 3 | Recruiting | Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 670 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | clinicaltrials.gov |
| March 12, 2026 | NCT07466147 | The Effect of Playful Physiotherapy Intervention | University of Tartu | Not applicable | Recruiting | Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder | 25 | Estonia | clinicaltrials.gov |
| February 27, 2026 | NCT07440225 | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) | EyeBiotech Ltd. | Phase 2/3 | Recruiting | Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration | 960 | Argentina, Australia, Estonia, Germany, Israel, Latvia, Poland, Puerto Rico... | clinicaltrials.gov |
| February 20, 2026 | NCT07422688 | Optical Coherence Tomography in Acute Vessel Evaluation | Aarhus University Hospital Skejby | Not applicable | Enrolling by invitation | Ischemic Heart Disease, Ischemic Coronary Artery Disease, ACS (Acute Coronary Syndrome) | 3,000 | Belgium, Denmark, Estonia, Finland, Italy, Latvia, New Zealand, Norway, Spain... | clinicaltrials.gov |
| January 22, 2026 | NCT07359846 | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) | Generate Biomedicines | Phase 3 | Recruiting | Severe Asthma | 786 | Argentina, Australia, Belgium, Estonia, France, Georgia, India, Ireland, Italy... | clinicaltrials.gov |
| December 23, 2025 | NCT07299019 | A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | Zenas BioPharma (USA), LLC | Phase 3 | Recruiting | Secondary Progressive Multiple Sclerosis | 990 | Australia, Belgium, Bulgaria, Croatia, Czechia, Estonia, France, Georgia... | clinicaltrials.gov |
| December 16, 2025 | NCT07286058 | Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis | Takeda | Phase 3 | Recruiting | Psoriatic Arthritis | 1,182 | Australia, China, Croatia, Czechia, Estonia, Germany, Hungary, Israel, Japan... | clinicaltrials.gov |
| December 11, 2025 | NCT07276490 | Central Haemodynamics and Pacing for AV Block | University of Tartu | Not applicable | Recruiting | Atrioventricular Block, Pacing Therapy, Right Ventricular Pacing, Conduction System Pacing | 124 | Estonia | clinicaltrials.gov |
| November 21, 2025 | NCT07241390 | A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney... | Eli Lilly and Company | Phase 3 | Recruiting | Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease | 7,140 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China... | clinicaltrials.gov |
| November 19, 2025 | NCT07235462 | A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a... | Bayer | Observational | Recruiting | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 2,000 | Austria, Belgium, Croatia, Denmark, Estonia, Finland, Germany, Italy, Latvia... | clinicaltrials.gov |
| November 6, 2025 | NCT07225504 | A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | Novartis Pharmaceuticals | Phase 3 | Recruiting | Secondary Progressive Multiple Sclerosis (SPMS) | 1,275 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China... | clinicaltrials.gov |
| November 3, 2025 | NCT07223814 | Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute... | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 | Recruiting | Acute Myeloid Leukemia | 875 | Australia, Austria, Belgium, Estonia, Finland, Germany, Japan, Netherlands... | clinicaltrials.gov |
| October 23, 2025 | NCT07220083 | A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) | Boehringer Ingelheim | Phase 3 | Recruiting | Focal Segmental Glomerulosclerosis | 286 | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Croatia... | clinicaltrials.gov |
| September 29, 2025 | NCT07196501 | A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 550 | Australia, Bulgaria, Canada, Estonia, Italy, Poland, Serbia, South Korea... | clinicaltrials.gov |
| September 24, 2025 | NCT07190209 | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic... | Sanofi | Phase 3 | Recruiting | Chronic Obstructive Pulmonary Disease | 942 | Argentina, Belgium, Brazil, Canada, Chile, China, Denmark, Estonia, Finland... | clinicaltrials.gov |
| August 22, 2025 | NCT07136467 | A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis... | AbbVie | Observational | Recruiting | Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa | 2,795 | Argentina, Canada, Colombia, Czechia, Estonia, France, Germany, Greece, Italy... | clinicaltrials.gov |
| July 29, 2025 | NCT07091630 | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | argenx | Phase 3 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy | 160 | Argentina, Austria, Brazil, Bulgaria, China, Colombia, Czechia, Denmark... | clinicaltrials.gov |
| July 22, 2025 | NCT07078487 | Effect of Paced HR on Central BP | University of Tartu | Not applicable | Completed | Sick Sinus Syndrome, Hypertension | 22 | Estonia | clinicaltrials.gov |
| July 20, 2025 | NCT07075016 | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered... | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 | Recruiting | Acute Myeloid Leukemia | 227 | Austria, Belgium, Denmark, Estonia, Finland, France, Germany, Ireland, Italy... | clinicaltrials.gov |
| July 16, 2025 | NCT07067463 | A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | Zenas BioPharma (USA), LLC | Phase 3 | Recruiting | Multiple Sclerosis (MS) Primary Progressive | 705 | Australia, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Italy... | clinicaltrials.gov |
| June 27, 2025 | NCT07042139 | No Reduction Compared to Closed Reduction for Distal Radius Fractures in Patients Over 65 or Older | Tampere University Hospital | Not applicable | Recruiting | Distal Radius Fracture, Casting, Closed Reduction | 532 | Denmark, Estonia, Finland, Sweden | clinicaltrials.gov |
| June 26, 2025 | NCT07038408 | Leave Nothing Behind Study Which Compares DCB With Bail Out BRS Versus BRS Strategy Alone | Ceric Sàrl | Not applicable | Recruiting | Drug Coated Balloon, Bioresorbable Scaffold, Percutaneous Coronary Intervention (PCI), Acute Coronary Syndrome (ACS) | 2,256 | Estonia | clinicaltrials.gov |
| June 24, 2025 | NCT07032662 | Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Immunovant Sciences GmbH | Phase 2 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy | 162 | Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil... | clinicaltrials.gov |
| June 11, 2025 | NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | IDEAYA Biosciences | Phase 3 | Recruiting | Uveal Melanoma | 520 | Australia, Austria, Belgium, Canada, Czechia, Denmark, Estonia, France... | clinicaltrials.gov |
| May 16, 2025 | NCT06975878 | Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | Sanofi | Phase 3 | Active not recruiting | Pneumococcal Immunization, Healthy Volunteers | 1,092 | Belgium, Czechia, Estonia, Finland, Germany, Greece, Italy, Poland | clinicaltrials.gov |
| May 14, 2025 | NCT06970015 | Demographics, Diagnosis, Management, and Outcomes of Non-occlusive Mesenteric Ischemia. | University of Tartu | Observational | Active not recruiting | Non-Occlusive Mesenteric Ischemia | 566 | Estonia | clinicaltrials.gov |
| May 11, 2025 | NCT06966401 | Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive... | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 850 | Australia, Belgium, Bulgaria, Canada, Croatia, Czechia, Estonia, Finland... | clinicaltrials.gov |
| April 17, 2025 | NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are... | European Myeloma Network B.V. | Phase 3 | Recruiting | Multiple Myeloma | 1,000 | Australia, Austria, Croatia, Czechia, Denmark, Estonia, Finland, Germany... | clinicaltrials.gov |
| April 17, 2025 | NCT06931717 | A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung... | ETOP IBCSG Partners Foundation | Phase 3 | Recruiting | Non-Small Cell Lung Cancer | 390 | Austria, Estonia, France, Germany, Ireland, Italy, Singapore, Spain, Switzerland | clinicaltrials.gov |
| April 16, 2025 | NCT06930625 | A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs | Debiopharm International SA | Phase 3 | Recruiting | Acromegaly | 119 | Austria, Belgium, Brazil, Bulgaria, Denmark, Estonia, France, Germany, Hungary... | clinicaltrials.gov |
| April 9, 2025 | NCT06920004 | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | argenx | Phase 3 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | 218 | Argentina, Australia, Austria, Brazil, Canada, Colombia, Czechia, Estonia... | clinicaltrials.gov |
| April 4, 2025 | NCT06912581 | Small Bowel Obstruction in Virgin Abdomen | University of Tartu | Observational | Completed | Small Bowel Obstruction Adhesion | 223 | Estonia | clinicaltrials.gov |
| March 18, 2025 | NCT06880744 | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab... | AbbVie | Phase 3 | Active not recruiting | Ulcerative Colitis | 573 | Austria, Bulgaria, Canada, China, Croatia, Czechia, Estonia, Finland, France... | clinicaltrials.gov |
| March 13, 2025 | NCT06873880 | Integrating BIA and eGFR for Nutritional Status in Hemodialysis Patients | University of Tartu | Observational | Recruiting | Chronic Kidney Disease Requiring Chronic Dialysis | 30 | Estonia | clinicaltrials.gov |
| March 6, 2025 | NCT06861361 | Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients | Ceric Sàrl | Not applicable | Recruiting | Symptomatic Severe Aortic Stenosis | 1,180 | Austria, Estonia, France, Germany, Hungary, Italy, Poland, Portugal, Romania... | clinicaltrials.gov |
| March 3, 2025 | NCT06855160 | A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When... | GlaxoSmithKline | Phase 3 | Recruiting | Chickenpox | 911 | Belgium, Estonia, Greece, Poland, Romania, Thailand, United States | clinicaltrials.gov |
| February 26, 2025 | NCT06846541 | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | Alumis Inc | Phase 3 | Active not recruiting | Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis | 1,680 | Australia, Bulgaria, Canada, Czechia, Estonia, France, Germany, Hungary, Japan... | clinicaltrials.gov |
| February 20, 2025 | NCT06838000 | Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants... | Sanofi Pasteur, a Sanofi Company | Phase 3 | Active not recruiting | Pneumococcal Infections | 1,268 | Estonia, Poland, Thailand, United States | clinicaltrials.gov |
| February 11, 2025 | NCT06820086 | Polygenic Risk Driven Pragmatic Statin Trial for Heart Disease Prevention | Mikk JÜRISSON | Phase 4 | Active not recruiting | PRS-based Primary Prevention of CVD | 2,714 | Estonia | clinicaltrials.gov |
| February 4, 2025 | NCT06806696 | SARS-COV-2 VARIANTS' EFFECT ON PREGNANCY AND LONG-TERM OUTCOMES AMONG PREGNANT WOMEN AND THEIR NEWBORNS IN ESTONIA | University of Tartu | Observational | Completed | Pregnancy, COVID-19, Post-COVID / Long-COVID, Newborn Health, Miscarriages | 60,739 | Estonia | clinicaltrials.gov |
| January 20, 2025 | NCT06784713 | DIFFERENT SARS-COV-2 VARIANTS' EFFECT ON THE COURSE OF COVID-19 IN ESTONIAN CHILDREN | University of Tartu | Observational | Completed | COVID - 19, Diabetes Mellitus, Post-COVID Conditions, MIS-C Associated With COVID-19 | 127,277 | Estonia | clinicaltrials.gov |
| January 10, 2025 | NCT06768788 | Long-term Impact of PE Teacher Interventions on Adolescent Leisure Time Activity and Motivation | University of Tartu | Not applicable | Active not recruiting | Physical Activity | 400 | Estonia | clinicaltrials.gov |
| December 18, 2024 | NCT06740630 | A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age | GlaxoSmithKline | Phase 3 | Recruiting | Chickenpox | 1,840 | Belgium, Colombia, Czechia, Dominican Republic, Estonia, Mexico, Poland, Puerto... | clinicaltrials.gov |
| December 3, 2024 | NCT06714123 | Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease | Vejle Hospital | Phase 2 | Recruiting | Pulmonary Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis | 140 | Denmark, Estonia, United Kingdom | clinicaltrials.gov |
| November 18, 2024 | NCT06693895 | A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age | GlaxoSmithKline | Phase 3 | Recruiting | Chickenpox | 750 | Bulgaria, Denmark, Estonia, Hong Kong, Lithuania, Mexico, Poland, United States | clinicaltrials.gov |
| November 12, 2024 | NCT06684847 | A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome | argenx | Phase 3 | Active not recruiting | Primary Sjogrens Disease | 631 | Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, China... | clinicaltrials.gov |
Sponsors posting most
| Sponsor | New trials | Latest |
|---|---|---|
| University of Tartu | 11 | May 28, 2026 |
| Tartu University Hospital | 3 | September 18, 2026 |
| Boehringer Ingelheim | 3 | March 27, 2026 |
| argenx | 3 | July 29, 2025 |
| GlaxoSmithKline | 3 | March 3, 2025 |
| North Estonia Medical Centre | 2 | September 24, 2026 |
| Zenas BioPharma (USA), LLC | 2 | December 23, 2025 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | 2 | November 3, 2025 |
| Neurocrine Biosciences | 2 | September 29, 2025 |
| Sanofi | 2 | September 24, 2025 |
| AbbVie | 2 | August 22, 2025 |
| Ceric Sàrl | 2 | June 26, 2025 |
| AstraZeneca | 1 | October 1, 2026 |
| Aalto University | 1 | September 29, 2026 |
| Odense University Hospital | 1 | August 11, 2026 |
| Helsinki University Central Hospital | 1 | May 12, 2026 |
| Mammograaf Radioloogiakliinik | 1 | April 29, 2026 |
| K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 1 | April 22, 2026 |
| EyeBiotech Ltd. | 1 | February 27, 2026 |
| Aarhus University Hospital Skejby | 1 | February 20, 2026 |
Conditions
| Condition group | New trials | Latest |
|---|---|---|
| Multiple Sclerosis, Chronic Progressive | 3 | December 23, 2025 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 3 | July 29, 2025 |
| Chickenpox | 3 | March 3, 2025 |
| Multiple Myeloma | 2 | August 11, 2026 |
| Depression | 2 | March 24, 2026 |
| Motor Activity | 2 | March 24, 2026 |
| Acute Coronary Syndrome | 2 | February 20, 2026 |
| Leukemia, Myeloid, Acute | 2 | November 3, 2025 |
| Depressive Disorder, Major | 2 | September 29, 2025 |
| COVID-19 | 2 | February 4, 2025 |
| Post-Acute COVID-19 Syndrome | 2 | February 4, 2025 |
| Carcinoma, Ovarian Epithelial | 1 | October 1, 2026 |
| Fallopian Tube Neoplasms | 1 | October 1, 2026 |
| Myocardial Infarction | 1 | September 24, 2026 |
| Treatment Adherence and Compliance | 1 | September 18, 2026 |
| Hypoparathyroidism | 1 | May 13, 2026 |
| Acute Kidney Injury | 1 | May 12, 2026 |
| Fever | 1 | May 12, 2026 |
| Out-of-Hospital Cardiac Arrest | 1 | May 12, 2026 |
| Heart Arrest | 1 | May 12, 2026 |
| Breast Neoplasms | 1 | April 29, 2026 |
| Ovarian Neoplasms | 1 | April 22, 2026 |
| Scleroderma, Systemic | 1 | March 27, 2026 |
| Chronic Pain | 1 | March 24, 2026 |
| Kinesiophobia | 1 | March 24, 2026 |
By phase
| Phase | New trials | Latest |
|---|---|---|
| Phase 3 | 30 | October 1, 2026 |
| Not applicable | 13 | September 29, 2026 |
| Observational | 12 | September 24, 2026 |
| Phase 2 | 3 | August 11, 2026 |
| Phase 2/3 | 1 | February 27, 2026 |
| Phase 4 | 1 | February 11, 2025 |
Where the register publishes
U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.